Clinical evaluation of tobramycin in respiratory and systemic infections in immunodepressed and normal patients.

@article{Altucci1976ClinicalEO,
  title={Clinical evaluation of tobramycin in respiratory and systemic infections in immunodepressed and normal patients.},
  author={Paolo Altucci and Gabriella Abbate and I. Alagia and V. Leonessa},
  journal={The Journal of infectious diseases},
  year={1976},
  volume={134 Suppl},
  pages={
          S182-6
        }
}
Twelve patients with acute or chronic pneumonia due mainly to gram-negative bacilli, two patients with pseudomonas endocarditis, and two patients with seratia sepsis were treated with 80-160 mg of tobramycin in two daily doses. Fourteen infected patients with underlying leukemia or lymphoma received this dose of tobramycin combined with cefazolin or penicillin. Most respiratory infections were cured or markedly improved. with eradication or significant reduction in the number of infecting… 
Treatment of respiratory infections in the patient at risk.
  • L. Young
  • Medicine, Biology
    The American journal of medicine
  • 1984
Cefotaxime is more effective than is ampicillin‐tobramycin in cirrhotics with severe infections
TLDR
The results suggest that broad‐spectrum cephalosporins should be considered as first choice antibiotics in cirrhotic patients with severe infections.
Tobramycin: an overview.
  • H. Neu
  • Biology
    The Journal of infectious diseases
  • 1976
TLDR
Tobinycin, one of the newest aminoglycoside agents, is the subject of this review and much of the material presented herein will be concerned with a comparison of tobramycin and other am inoglycosides, since only in this context can one determine the proper role for this agent.
BIRC7 (baculoviral IAP repeat containing 7)
TLDR
The role of BIRC7 in cancer cell biology and its clinical significance is focused on, demonstrating aspects of its DNA/RNA and protein, as well as its relevance in cancer diagnosis and prognosis.

References

SHOWING 1-6 OF 6 REFERENCES
Clinical evaluation of tobramycin in urinary tract infections.
TLDR
Twenty-one patients with urinary tract infections due to Pseudomonas and coli-form bacilli were treated with 80-120 mg of tobramycin per day in two daily doses and urine cultures demonstrated rapid sterilization in the cases in which patients responsed well.
Clinical and laboratory studies with tobramycin.
TLDR
31 patients suffering from infections caused by gram-negative organisms, including 18 due to Ps.
Therapeutic trials with tobramycin
TLDR
Tobramycin has a spectrum of antibacterial activity similar to gentamicin and appears to be as effective in the therapy of gram-negative infections and may be less nephrotoxic than Gentamicin.
Tobramycin in Bronchial Secretions
TLDR
The penetration of tobramycin sulfate into normal lower respiratory tract secretions was studied in a dog model and the maximum tobramYcin concentration in bronchial fluids was equal to the mean inhibitory concentrations that have been reported for about 80% of Pseudomonas isolates.
Pharmacokinetics of Tobramycin in Patients with Stable Renal Impairment, Patients Undergoing Peritoneal Dialysis, and Patients on Chronic Hemodialysis
The pharmacokinetics of tobramycin were studied in five patients with stable renal impairment, four patients requiring peritoneal dialysis, and four patients on chronic hemodialysis. The half-life of
[Tobramycin: clinical and microbiological evaluation].